A Phase I, Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics of Orally Administered [14C]-Roniciclib (BAY 1000394) in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2016
At a glance
- Drugs Roniciclib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Bayer
- 14 Jul 2016 Status changed from active, no longer recruiting to completed.
- 05 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Jul 2016.
- 12 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.